Travere Therapeutics (TVTX) Other Working Capital Changes (2013 - 2025)

Travere Therapeutics has reported Other Working Capital Changes for 13 years, with the latest figure at -$4.5 million in Q2 2025.

• For the quarter ending Q2 2025, Other Working Capital Changes fell 232.69% year-over-year to -$4.5 million; the trailing twelve-month figure through Mar 2026 stood at -$4.5 million (down 53.39% YoY), and the FY2025 full-year result was -$2.8 million, up 53.97% from the prior year.
• Other Working Capital Changes for Q2 2025 stood at -$4.5 million, down from $1.7 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $36.3 million in Q4 2021, with the low at -$11.2 million in Q3 2022.
• Historically, Other Working Capital Changes has averaged $36722.2 across 5 years, with a median of -$517000.0 in 2021.
• The largest YoY upside for Other Working Capital Changes was 508.97% in 2022 against a maximum downside of 1468.33% in 2022.
• Travere Therapeutics' Other Working Capital Changes stood at $36.3 million in 2021, then tumbled by 111.12% to -$4.0 million in 2022, then tumbled by 38.4% to -$5.6 million in 2023, then slumped by 97.51% to -$11.0 million in 2024, then soared by 59.3% to -$4.5 million in 2025.
• The last three Other Working Capital Changes figures came in at -$4.5 million (Q2 2025), $1.7 million (Q1 2025), and -$11.0 million (Q4 2024), per Business Quant data.